@misc{10481/91102,
year = {2023},
month = {12},
url = {https://hdl.handle.net/10481/91102},
abstract = {Colorectal cancer (CRC) is a highly prevalent form of neoplasm worldwide. Capecitabine,
an oral antimetabolite, is widely used for CRC treatment; however, there exists substantial variation in
individual therapy response. This may be due to genetic variations in genes involved in capecitabine
pharmacodynamics (PD). In this study, we investigated the role of single-nucleotide polymorphisms
(SNPs) related to capecitabine’s PD on disease-free survival (DFS) in CRC patients under adjuvant
treatment. Thirteen SNPs in the TYMS, ENOSF1, MTHFR, ERCC1/2, and XRCC1/3 genes were
genotyped in 142 CRC patients using real-time PCR with predesigned TaqMan® probes. A significant
association was found between favorable DFS and the ENOSF1 rs2612091-T allele (p = 0.010;
HR = 0.34; 95% CI = 0.14–0.83), as well as with the TYMS/ENOSF1 region ACT haplotype (p = 0.012;
HR = 0.37; 95% CI = 0.17–0.80). Other factors such as low histological grade (p = 0.009; HR = 0.34;
95% CI = 0.14–0.79) and a family history of cancer (p = 0.040; HR = 0.48; 95% CI = 0.23–0.99) were also
linked to improved DFS. Therefore, the SNP ENOSF1 rs2612091 could be considered as a predictive
genetic biomarker for survival in CRC patients receiving capecitabine-based adjuvant regimens.},
organization = {Grants co-funded
by ERDF funds (EU) from the Instituto de Salud Carlos III (PT13/0010/0039)},
publisher = {MDPI},
keywords = {Colorectal cancer},
keywords = {Capecitabine},
keywords = {Pharmacodynamics},
title = {Role of Single-Nucleotide Polymorphisms in Genes Implicated in Capecitabine Pharmacodynamics on the Effectiveness of Adjuvant Therapy in Colorectal Cancer},
doi = {10.3390/ijms25010104},
author = {Cura, Yasmin and Sánchez Martín, Almudena and Márquez Pete, Noelia and González Flores, Encarnación and Martínez-Martínez, Fernando and Pérez Ramírez, Cristina and Jiménez Morales, Alberto},
}